Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors Emiliano Calvo, Maria Alsina, Jan H.M. Schellens, Alwin DR Huitema, Josep Tabernero, Aurelia de Vries-Schultink, Valentina Boni, Bernard Doger, Cecile Geuijen, Robert Doornbos, Kees Bol, Martine Westendorp, Mark Throsby, Lex Bakker and Setareh Shamsili
Title A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
Journal Cancer Res
Vol
Issue
Date
URL http://cancerres.aacrjournals.org/content/76/14_Supplement/CT050.short
Abstract Text Cancer Res 2016;76(14 Suppl):Abstract nr CT050

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Zenocutuzumab MCLA-128|MCLA128|MCLA 128 Zenocutuzumab (MCLA-128) is a bispecific antibody that targets Erbb2 (Her2) and Erbb3, resulting in antibody-dependent cell-mediated cytotoxicity against tumor cells (Cancer Res 2016;76(14 Suppl):Abstract nr CT050, PMID: 32054397).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable Zenocutuzumab Phase Ib/II Actionable In a Phase I/II trial, Zenocutuzumab (MCLA-128) resulted in stable disease for 5 months in a patient with colorectal cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Unknown unknown lung non-small cell carcinoma not applicable Zenocutuzumab Phase Ib/II Actionable In a Phase I/II trial, Zenocutuzumab (MCLA-218) resulted in partial response for more than 10 months in a patient with non-small cell lung cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Unknown unknown Advanced Solid Tumor not applicable Zenocutuzumab Phase Ib/II Actionable In a Phase I/II trial, Zenocutuzumab (MCLA-128) demonstrated safety and preliminary efficacy, resulted in partial response in 3.6% (1/28) and stable disease in 7.1% (2/28) of patients with advanced solid tumors (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Unknown unknown gastroesophageal junction adenocarcinoma not applicable Zenocutuzumab Phase Ib/II Actionable In a Phase I/II trial, Zenocutuzumab (MCLA-128) resulted in stable disease for 5 months in a patient with gastroesophageal junction cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...